NasdaqGS:TSHABiotechs
How Investors Are Reacting To Taysha Gene Therapies (TSHA) Stronger MeCP2 Expression Data In Rett Program
Taysha Gene Therapies recently reported preclinical in vitro data showing its self-complementary AAV9 vector produced roughly 30-fold higher MeCP2 protein expression than a single-stranded AAV9 approach, while its miniMeCP2 construct maintained stable, functional expression in neuronal cells.
These findings add biological support for the design of TSHA-102 in Rett syndrome and offer additional translational evidence backing its ongoing Phase 1/2 clinical trials.
Next, we’ll examine how this...